retatrutide expanded access program Eli lilly will provide limited early to its experimental obesity drug, retatrutide, for eligible patients before US FDA approval. The access is aimed at adults with severe, treatment-resistant obesity retatrutide expanded access program eli
Pay in 4 interest-free payments of $6.93 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26





















